Market Place
Sourcing Support
Syros flunks phase 3 blood cancer trial, triggering loan default
14 Nov 2024 //
FIERCE BIOTECH
Syros Announces Topline Data from SELECT-MDS-1 Trial in MDS
12 Nov 2024 //
BUSINESSWIRE
Syros To Report Q3 2024 Financial Results On Oct 31
24 Oct 2024 //
BUSINESSWIRE
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
27 Aug 2024 //
BUSINESSWIRE
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
12 Aug 2024 //
BUSINESSWIRE
Syros Reports Q2 2024 Results And Provides Business Update
31 Jul 2024 //
BUSINESSWIRE
Syros To Report Q2 2024 Results On July 31
24 Jul 2024 //
BUSINESSWIRE
Syros To Host Webcast On MDS, Tamibarotene Opportunity In RARA Overexpression
13 Jun 2024 //
BUSINESSWIRE
Syros Reports Q1 2024 Results, Corporate Update
14 May 2024 //
BUSINESSWIRE
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
07 May 2024 //
BUSINESSWIRE
Syros to Participate in Upcoming Investor Conferences
07 May 2024 //
BUSINESSWIRE
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Apr 2024 //
BUSINESSWIRE
Syros Reports Fourth Quarter and Full Year 2023 Financial Results
27 Mar 2024 //
BUSINESSWIRE
Syros to Participate in TD Cowen 44th Annual Health Care Conference
27 Feb 2024 //
BUSINESSWIRE
Syros Highlights 2024 Milestones to Deliver on the Value of Tamibarotene
08 Jan 2024 //
BUSINESSWIRE
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock
19 Dec 2023 //
BUSINESSWIRE
Syros’ stock up after sharing early, mid-stage AML data
07 Dec 2023 //
FIERCE BIOTECH
Syros Announces Initial Data from Phase 2 Trial Evaluating Tamibarotene
06 Dec 2023 //
BUSINESSWIRE
Syros Announces Planned CEO Leadership Transition
02 Oct 2023 //
BUSINESSWIRE
After 2 partners walk away, Syros cuts 35% of workforce
02 Oct 2023 //
FIERCE BIOTECH
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Sep 2023 //
BUSINESSWIRE
Incyte drops Syros blood cancer partnership, following Pfizer
15 Aug 2023 //
FIERCE BIOTECH
Syros Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Aug 2023 //
BUSINESSWIRE
Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
01 Aug 2023 //
BUSINESSWIRE
Pfizer to end licence deal with Syros for blood disorder therapies
22 Jul 2023 //
BUSINESS TIMES
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jul 2023 //
BUSINESSWIRE
Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference
08 Jun 2023 //
BUSINESSWIRE
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Jun 2023 //
BUSINESSWIRE
Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609
25 May 2023 //
BUSINESSWIRE
Syros Reports 1Q 2023 FYR and Provides a Corporate Update
10 May 2023 //
BUSINESSWIRE
Syros to Present at JMP Securities 2023 Life Sciences Conference
09 May 2023 //
BUSINESSWIRE
Syros Reports Fourth Quarter and Full Year 2022 Financial Results
02 Mar 2023 //
BUSINESSWIRE
Syros to Participate in Upcoming Investor Conferences in March
28 Feb 2023 //
BUSINESSWIRE
Syros to Report Fourth Quarter and Full Year 2022 Financial Results
23 Feb 2023 //
BUSINESSWIRE
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Feb 2023 //
BUSINESSWIRE
Syros Receives Fast Track Designation from the FDA for Tamibarotene
26 Jan 2023 //
BUSINESSWIRE
Syros Announces Clinical Updates and 2023 Strategic Priorities
09 Jan 2023 //
BUSINESSWIRE
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23 Dec 2022 //
BUSINESSWIRE
Syros Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene
12 Dec 2022 //
BUSINESSWIRE
Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial
10 Dec 2022 //
BUSINESSWIRE
Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data
05 Dec 2022 //
BUSINESSWIRE
Syros to Participate at Piper Sandler 34th Annual Healthcare Conference
22 Nov 2022 //
BUSINESSWIRE
Syros Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
BUSINESSWIRE
3 more biotechs look to cull, partner assets
14 Nov 2022 //
FIERCEBIOTECH
Syros to Report Third Quarter 2022 Financial Results on November 14, 2022
07 Nov 2022 //
BUSINESSWIRE
Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial
03 Nov 2022 //
BUSINESSWIRE
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Oct 2022 //
BUSINESSWIRE
Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders
20 Sep 2022 //
SEEKING ALPHA
Syros Announces Closing of Merger with Tyme Tech & Concurrent Private Placement
16 Sep 2022 //
BUSINESSWIRE
Syros and Tyme Technologies Announce Stockholder Approval of Merger
15 Sep 2022 //
BUSINESSWIRE
Syros Receives FDA Orphan Drug Designation for SY-5609 for Pancreatic Cancer
13 Sep 2022 //
BUSINESSWIRE
Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference
07 Sep 2022 //
BUSINESSWIRE
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Sep 2022 //
BUSINESSWIRE
Syros Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
BUSINESSWIRE
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Aug 2022 //
BUSINESSWIRE
Syros Receives Positive Opinion on Orphan Drug Designation from the EMA
03 Aug 2022 //
BUSINESSWIRE
Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
02 Aug 2022 //
BUSINESSWIRE
Syros buys Tyme, securing $190M to extend cash runway into 2025
06 Jul 2022 //
FIERCEBIOTECH
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Jul 2022 //
BUSINESSWIRE
